

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



16th June, 2020

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Update on Submission of Quick Result.

In reference to our submission of outcome and quick results of our company as on the Board meeting held on 15th June, 2020 and in reference to the above mentioned subject, we herewith submit to the Exchange the cash flow statement forming part of the quick result for the quarter and year ended 31st March, 2020 as approved by the Board of Directors at their meeting held on 15th June, 2020.

Accordingly also find attached the certificate of CEO and CFO attached.

Inadvertently the same got missed out, request you to take the same into consideration.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,
For **Krebs Biochemicals & Industries Limited**



Taruni Banda
Company Secretary


Encl as above

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912
Cash Flow Statement for the Year Ended 31.03.2020

(Rs in Lacs)

Particulars	Year Ended 31.03.2020	Year Ended 31.03.2019
Cash Flow from Operating Activities		
Net Profit before tax and exceptional items	(2,887.20)	(2,012.24)
Adjustments for:		
Depreciation and Amortisation Expenses	467.90	440.23
Financial Charges	592.78	623.80
Other Income	(36.52)	(33.06)
Operating Profit before Working Capital Changes	(1,863.04)	(981.27)
Changes in Working Capital		
(Increase)/Decrease in Inventories	(603.19)	276.47
(Increase)/Decrease in Trade Receivables	270.89	(258.61)
(Increase)/Decrease in Other Financial Assets	12.86	(15.91)
(Increase)/Decrease in Other Current Assets	(183.34)	314.28
(Increase)/Decrease in Financial Assets	(8.31)	(35.44)
(Increase)/Decrease in Other Non Current Assets	126.30	(215.25)
Increase/(Decrease) in Non Current Provisions	(180.66)	6.61
Increase/(Decrease) in Retirement Benefit obligations	14.99	29.56
Increase/(Decrease) in Current Provisions	17.97	12.63
Increase/(Decrease) in Retirement Benefit obligations	38.03	4.55
Increase/(Decrease) in Trade Payables	125.53	378.68
Increase/(Decrease) in Other Current financial liabilities	(1,392.41)	465.76
Increase/(Decrease) in Other Current Liabilities	38.11	407.45
Cash generated from Operations	(1,723.22)	1,370.79
Net Cash Flow from Operating Activities	(3,586.27)	389.51
(Increase)/Decrease of Property, Plant & Equipment	(870.01)	(433.89)
(Increase)/Decrease of Capital Work-in-Progress	(71.11)	55.49
(Increase)/Decrease of Other Intangible Assets	-	(56.04)
(Increase)/Decrease of Intangible assets under development	-	(30.18)
Other Income	36.52	33.06
Cash Flow from Investing Activities	(904.60)	(431.56)
Increase/(Decrease) in long term borrowings	1,506.70	(206.98)
Increase/(Decrease) in Share Capital	137.00	288.63
Increase/(Decrease) in Share Premium	1,041.20	2,193.59
Increase/(Decrease) in Share Warrants	765.40	-
Financial Charges	(592.78)	(623.80)
Increase/(Decrease) in Other Financial Liabilities	(81.11)	80.66
Cash Flow from Financing Activities	2,776.41	1,732.09
Net Increase (Decrease) in Cash and Cash equivalents	(1,714.46)	1,690.05
Cash and Cash equivalents as at the beginning of the year	1,731.89	41.84
Cash and Cash equivalents at the end of the year	17.43	1,731.89

For KREBS BIOCHEMICAL & INDUSTRIES LTD.



Company Secretary

ACS-46673

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



MANAGING DIRECTOR AND CFO CERTIFICATION AS PER SEBI (LODR) REGULATIONS, 2015

In compliance with Regulation 17 (8) read with Schedule II Part B of the SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015 Listing Agreement with the Stock Exchange, I hereby certify that:

a. We have reviewed financial statements and the Cash Flow Statement for the year 2019-20 and that to the best of our knowledge and belief:

i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

ii) these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

b. There are to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or violative of the company's code of conduct.


c. We accept the responsibility for establishing and maintaining internal controls and that we have evaluated the effectiveness of the internal control systems of the company and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of the internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

d. We have indicated to the auditors and the Audit Committee:

i) significant changes in internal control during the year;

ii) significant changes in accounting policies during the year and that the same have been disclosed in the notes of the financial statements; and

iii) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the company's internal control system.


AVINASH RAVI


Managing Director

DIN-01616152




RAVI BABU

Chief Financial Officer (KMP)



Place: Hyderabad

Dt: 15-06-2020